Perioperative SOX treatment significantly improved 3-year disease-free survival in patients with locally advanced gastric cancer compared with adjuvant CapOx.

Results from a phase 2 clinical trial of the use of zanidatamab with standard first-line chemotherapy in patients with HER2-positive GEA show promising disease control rate and duration of response.

Results from a second-line trastuzumab deruxtecan phase 2 study in patients with HER2-positive metastatic gastric or gastroesophageal junction cancer reveal promising response and safety.

Comprehensive analysis of immune checkpoints in gastric adenocarcinoma finds ICOSLG and CD70 may serve as prognostic biomarkers for gastric cancer.

Updated clinical data from the PANTHERA study shows promising efficacy for pembrolizumab triple therapy in HER2-positive advanced gastric and gastroesophageal junction (GEJ) cancer regardless of a patient’s PD-L1 status.

Three-year ATTRACTION-2 follow-up results confirm the long-term efficacy of nivolumab in patients with previously treated advanced gastric/gastroesophageal junction (GEJ) cancer.

KEYNOTE-181 results show improved overall survival in patients with advanced esophageal cancer treated with second-line pembrolizumab compared with chemotherapy.

Recommendations for the clinical management of patients with advanced esophageal cancer and gastroesophageal junction adenocarcinoma were released by an expert panel.

Differences in survival time by tumor response were found during evaluation of nivolumab therapy in advanced gastric cancer.

The use of PET to direct therapy after nonresponse to induction chemotherapy improved overall survival in patients with resectable esophageal cancer.